NCT01391663View on ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Pharmacokinetics and Pharmacodynamics
Interventions
DRUG

Alogliptin

Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.

DRUG

Alogliptin

Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.

DRUG

Alogliptin

Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.

Trial Locations (1)

Unknown

Seoul

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY